Pages that link to "Q40561489"
Jump to navigation
Jump to search
The following pages link to A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels (Q40561489):
Displaying 50 items.
- Role of key TYMS polymorphisms on methotrexate therapeutic outcome in portuguese rheumatoid arthritis patients (Q21131938) (← links)
- A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance (Q24679991) (← links)
- The association between two polymorphisms in the TS gene and risk of cancer: a systematic review and pooled analysis (Q26866504) (← links)
- UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy (Q27851574) (← links)
- Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy (Q27863360) (← links)
- G>C SNP of thymidylate synthase with respect to colorectal cancer (Q27863368) (← links)
- Pathway based analysis of SNPs with relevance to 5-FU therapy: relation to intratumoral mRNA expression and survival. (Q27863385) (← links)
- Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines (Q28534572) (← links)
- Thymidylate synthase expression and prognosis in colorectal cancer: a meta-analysis of colorectal cancer survival data. (Q30570866) (← links)
- Polymorphisms in thymidylate synthase gene and susceptibility to breast cancer in a Chinese population: a case-control analysis (Q33244608) (← links)
- Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker (Q33337970) (← links)
- Pancytopenia and Severe Gastrointestinal Toxicities Associated with 5-Fluorouracil in a Patient with Thymidylate Synthase (TYMS) Polymorphism (Q33436235) (← links)
- Loss of heterozygosity at thymidylate synthase locus in Barrett's metaplasia, dysplasia, and carcinoma sequences (Q33449893) (← links)
- Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years (Q34008793) (← links)
- Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application (Q34136250) (← links)
- Genetic variation in microRNA networks: the implications for cancer research (Q34177121) (← links)
- Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients (Q34491507) (← links)
- Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs? (Q34559803) (← links)
- A systematic analysis of disease-associated variants in the 3' regulatory regions of human protein-coding genes II: the importance of mRNA secondary structure in assessing the functionality of 3' UTR variants (Q34568722) (← links)
- Genes and abdominal aortic aneurysm (Q34683905) (← links)
- MTHFR Glu429Ala and ERCC5 His46His polymorphisms are associated with prognosis in colorectal cancer patients: analysis of two independent cohorts from Newfoundland. (Q34692175) (← links)
- One-carbon metabolism gene polymorphisms and risk of non-Hodgkin lymphoma in Australia (Q34692324) (← links)
- MicroRNA-433 negatively regulates the expression of thymidylate synthase (TYMS) responsible for 5-fluorouracil sensitivity in HeLa cells (Q34894800) (← links)
- One-carbon metabolism pathway gene variants and risk of clear cell renal cell carcinoma in a Chinese population (Q35053902) (← links)
- Nutrients and Genetic Variation Involved in One-Carbon Metabolism and Hodgkin Lymphoma Risk: A Population-based Case-Control Study (Q35465901) (← links)
- NAT1, NOS3, and TYMS genotypes and the risk of conotruncal cardiac defects. (Q35500353) (← links)
- Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery (Q35583987) (← links)
- Part 4: Pharmacogenetic Variability in Anticancer Pharmacodynamic Drug Effects (Q35584647) (← links)
- Genetic variants in 3'-UTRs of methylenetetrahydrofolate reductase (MTHFR) predict colorectal cancer susceptibility in Koreans. (Q35687058) (← links)
- Genetic variant rs16430 6bp > 0bp at the microRNA-binding site in TYMS and risk of sporadic breast cancer risk in non-Hispanic white women aged ≤ 55 years (Q35731144) (← links)
- Association between folate metabolism-related polymorphisms and colorectal cancer risk (Q35753712) (← links)
- Polymorphism in one-carbon metabolism pathway affects survival of gastric cancer patients: Large and comprehensive study (Q35832445) (← links)
- Delimiting Allelic Imbalance of TYMS by Allele-Specific Analysis (Q35858190) (← links)
- Pharmacogenomics and stomach cancer. (Q35873676) (← links)
- Pharmacogenetics of methotrexate (Q35911142) (← links)
- Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea (Q36026126) (← links)
- Predictive diagnostics in colorectal cancer: impact of genetic polymorphisms on individual outcomes and treatment with fluoropyrimidine-based chemotherapy (Q36117701) (← links)
- Genetic factors influencing pyrimidine-antagonist chemotherapy. (Q36205831) (← links)
- Pharmacogenetics of folate-related drug targets in cancer treatment (Q36278007) (← links)
- Pharmacogenetics of colorectal cancer (Q36326214) (← links)
- The Effectiveness of Pemetrexed Monotherapy Depending on Polymorphisms in TS and MTHFR Genes as Well as Clinical Factors in Advanced NSCLC Patients. (Q36378565) (← links)
- Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy (Q36441493) (← links)
- A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202 (Q36459140) (← links)
- The role of pharmacogenetics in cancer therapeutics (Q36536674) (← links)
- Genetic markers of treatment response in rheumatoid arthritis (Q36863231) (← links)
- Thymidylate synthase polymorphisms, folate and B-vitamin intake, and risk of colorectal adenoma. (Q36610609) (← links)
- Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)--novel predictors for response and survival in gastric cancer patients (Q36613622) (← links)
- Association of thymidylate synthase gene 3'-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC (Q36624188) (← links)
- Genetic polymorphisms in the methylenetetrahydrofolate reductase and thymidylate synthase genes and risk of hepatocellular carcinoma (Q36667860) (← links)
- Folate-related polymorphisms in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome (Q36695209) (← links)